LUND, Sweden, Nov. 12, 2020 /PRNewswire/ -- Immunovia has
today published third quarter interim report for January -
September 2020. It is available
on Immunovia's website.
"The most important event during Q3 was that we announced
positive results from the IMMray™ PanCan-d verification study. The
analysis from the verification study showed results in line with
the previous commercial test model study (CTMS) and was the
beginning of the last stage towards CLIA-CAP accreditation in the
USA, the final blind validation
study.
Q3 started with a virtual presentation by Immunovia's
Thomas King, MD, Ph.D. and
Laura Chirica, Ph.D., at the annual
meeting of the International Association of Pancreatology (IAP) at
the European Pancreatic Club (EPC) on July
2, 2020, one of the most important events in the world in
the field of pancreatic cancer.
In July, we launched the "Immunovia Walk Around the World to
Raise Awareness for Pancreatic Cancer", an initiative to raise
awareness of pancreatic cancer.
In early September, the second webinar in the IMMray™ PanCan-d
series was hosted with Linda Mellby,
Ph.D., Thomas King, MD, Ph.D. and
Laura Chirica, Ph.D., who gave a
more detailed presentation of the results of the Commercial Test
Model Study (CTMS).
We announced the appointment of Patrik
Dahlen as our new CEO starting on November 1, 2020, and that Mats Grahn will continue as a board member.
I am pleased to hand over the baton to Patrik Dahlen, who I have known for a long time
and who is one of the most experienced leaders in the international
diagnostics industry. Patrik is not only a highly respected
business leader with wide-ranging international experience and
knowledge of the international diagnostics industry, but he also
knows Immunovia well, from the ground up, as he was one of our
board members during the initial years," commented, Mats Grahn, outgoing CEO and current board
member of Immunovia AB.
"I am honored to join Immunovia during this pivotal and exciting
time in the company's history. I believe that Immunovia is in a
position to evolve into a dominating market leader for the
blood-based diagnosis of pancreatic cancer and I look forward to
the exciting times to come in the company's development.
I would like to emphasize that Immunovia continues to have the
goal of a long-term market penetration of 30% after reimbursement
and widespread coverage has been achieved. The current size of the
addressable market for IMMray™ PanCan-d is estimated to exceed
USD 4 billion in the EU and the
USA, across the three risk groups
the company targets: hereditary/familial, differential diagnosis of
early symptoms and newly diagnosed diabetes in individuals over 50.
We look forward to continuing to work with healthcare operators
around the world.
On behalf of the Board and the entire Immunovia team, I thank
you for your continued support of Immunovia's efforts to contribute
to having a positive impact on the lives of those at risk from
pancreatic cancer, "Patrik Dahlen,
CEO, Immunovia.
- Excerpt from the CEO comments from the report
Third Quarter Interim Report January - September 2020 Call Details:
Immunovia invites to a teleconference (in English) for
investors, analysts and media on Thursday,
November 12, 2020 at 16:30
CET.
Patrik Dahlen, CEO will present
Immunovia and comment on the interim report for the period January
- September 2020 followed by a
Q&A session.
Please call in a few minutes in advance. To attend, please
dial-in at one of the numbers below and provide the conference
code Immunovia to the operator:
Conference Call
Sweden: +46 (0) 8 50520424
United States: +1 212 999
6659
France: +33 (0) 1 7037 7166
Denmark: +45 3272 9273
Germany: +49 (0) 30 3001
90612
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 708
5073
Norway: +47 2 156
3318
Austria: +43 (0)
12530807
Switzerland: +41 (0) 22 592
7915
United Kingdom (Standard
International Access): +44 (0) 20 3003 2666
Conference Code: (to provide to the operator)
Immunovia
Immunovia
Webcast: https://channel.royalcast.com/immunovia/#!/immunovia/20201112_1
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia's webpage under
Investors/Financial Reports
(http://immunovia.com/investors/financial-reports/) for those who
want to listen to the telephone conference afterwards. The file
will be available within two hours after the conference has
ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-reports-third-quarter-interim-report-january---september-2020,c3236271
The following files are available for download:
https://mb.cision.com/Main/13121/3236271/1334471.pdf
|
Release
|